2023 World Conference on Lung Cancer (Posters)-EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression

EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the real-world outcomes of immunotherapy compared to chemoimmunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The researchers analyzed data from COTA's real-world database and identified patients diagnosed with mNSCLC on or after January 1, 2017, with 50% PD-L1 expression and without specific genetic alterations. The patients were divided into two groups: those who received single-agent immune-checkpoint inhibitors (ICI) and those who received combination chemoimmunotherapy (ICIchemo) as their first-line treatment. The study compared the time to next treatment (TTNT), progression-free survival (PFS), and overall survival (OS) between the two groups.<br /><br />The study included a total of 241 patients, with 133 in the ICI group and 108 in the ICIchemo group. Both groups had similar rates of non-squamous histology and smoking history. The ICI group had an older median age, while the ICIchemo group had a higher proportion of patients with no comorbidities. In unadjusted analysis, the ICIchemo group had a longer median TTNT compared to the ICI group. However, after adjusting for baseline characteristics, the trend persisted but was not statistically significant. The adjusted PFS was numerically better in the ICIchemo group, but the difference did not reach statistical significance. The adjusted median OS was also longer in the ICIchemo group, but again, the difference was not statistically significant.<br /><br />The study concludes that although there was a marginal difference in TTNT between the two treatment groups, this did not translate into a statistically significant difference in survival. The findings suggest that there may not be a significant benefit to adding chemotherapy to immunotherapy in this specific patient population. However, the researchers acknowledge that the limited follow-up time may have impacted the results, and further research with longer follow-up is needed to confirm these findings.

Asset Subtitle

Kaushal Parikh

Meta Tag

Speaker Kaushal Parikh

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immunotherapy

chemoimmunotherapy

metastatic non-small cell lung cancer

NSCLC

PD-L1 expression

real-world outcomes

time to next treatment

progression-free survival

overall survival

genetic alterations